SOX8 Knockout MHCC97-H Cell Line

The SOX8 Knockout MHCC97-H Cell Line is a CRISPR/Cas9-edited knockout cell line designed for the targeted disruption of the SOX8 gene in a human hepatocellular carcinoma (HCC) background. This loss-of-function model enables robust interrogation of SOX8-dependent signaling networks and phenotypic outcomes without introducing artifacts associated with transient silencing methods. The knockout cell line is stringently validated to ensure gene disruption while maintaining the essential characteristics of the parental MHCC97-H cells, providing a reliable tool for mechanistic and translational studies in liver cancer biology.

The parental MHCC97-H cell line is a highly metastatic human HCC line established from a nude mouse model of human hepatocellular carcinoma. It is widely recognized for its aggressive metastatic properties and is extensively utilized to investigate the molecular mechanisms driving HCC progression, invasion, and drug resistance. This cellular model recapitulates key clinical features of advanced liver cancer, including robust migration and invasion capacities, making it particularly suitable for studies on tumor metastasis and the epithelial-mesenchymal transition (EMT). The knockout cell line retains the critical malignant traits of the MHCC97-H background, enabling direct attribution of phenotypic changes to SOX8 loss.

SOX8 is an oncogenic transcription factor that integrates multiple signaling inputs to promote liver cancer aggressiveness. It is activated downstream of Wnt/??-catenin signaling, where ??-catenin interacts with TCF4 and CBP/p300 co-activators to drive target gene expression. SOX8 also responds to TGF-??/Smad2/3 cascades, STAT3, and NF-??B pathways. Once activated, SOX8 transcriptionally upregulates key EMT transcription factors such as SNAI1 (Snail) and SNAI2 (Slug), which in turn suppress epithelial markers and enhance mesenchymal traits. SOX8 also promotes cell cycle progression through CCND1 (Cyclin D1) and MYC, and facilitates extracellular matrix degradation by inducing MMP9. Additionally, SOX8 can interact with SOX9 and modulates signals from MAPK/ERK and PI3K/AKT axes, thereby regulating proliferation, survival, and invasive motility in HCC cells.

In the MHCC97-H context, SOX8 ablation disrupts these oncogenic programs, leading to reduced metastatic potential and enhanced sensitivity to chemotherapeutic agents. By eliminating SOX8-mediated transcriptional control over EMT and proliferation pathways, the knockout cell line serves as a critical tool for dissecting the molecular basis of HCC metastasis and drug resistance. It enables researchers to delineate the relative contributions of Wnt/??-catenin and TGF-?? signaling in driving SOX8-dependent phenotypes and to identify synthetic lethal interactions or compensatory mechanisms that may inform therapeutic strategies.

This knockout cell line is ideally suited for a variety of advanced research applications, including functional genomics, drug target validation, and pathway analysis. Users can employ Transwell migration and invasion assays, wound healing assays, and CCK-8 proliferation measurements to quantify loss-of-function effects on metastatic behavior. Transcriptomic profiling by RNA-seq and targeted gene expression analysis via RT-qPCR can reveal SOX8-driven gene networks, while ChIP assays can map SOX8 binding to chromatin. In vivo metastasis models with these cells allow preclinical evaluation of metastatic suppression. For further details or custom inquiries, please contact Ascent Research.